Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juvenile indication for Orencia

Executive Summary

FDA approves Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacep) for moderately to severely active polyarticular juvenile iodiopathic arthritis in pediatric patients six years and older, April 8. The same day, Bristol and Repligen reach an out-of-court settlement regarding royalties due on U.S. sales of the drug. The settlement includes $5 million in past royalties to Repligen and the University of Michigan, the original owner of the patent covering anti-CTLA-4 antibodies. Orencia enters a market that includes Abbott's tumor necrosis factor inhibitor Humira (adalimumab), which was approved in February
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel